Galapagos announces expanded drug discovery collaboration with
Schering-Plough
(Thomson Reuters ONE) - Mechelen, Belgium and Saffron Walden, UK; 24 September 2009 -Galapagos NV (Euronext: GLPG) announces today that its servicedivision, BioFocus DPI, has initiated a drug discovery collaborationwith Schering-Plough Research Institute (SPRI). Under the terms ofthe agreement, BioFocus DPI will perform medicinal chemistry withsupporting biology and ADME/PK services for multiple Schering-Ploughdrug discovery projects. Total contract value for Galapagos is ?2.8M over a one year period.Building on a collaboration established in May 2009 and expanded thismonth, BioFocus DPI scientists will work with two of SPRI's Europeansites on these drug discovery projects."We are pleased to build on our collaborative relationship with SPRI,which has evolved into one of the larger for BioFocus DPI this yearwith over 20 research staff currently engaged," said Onno van deStolpe, CEO of Galapagos. "BioFocus DPI has proven resilient insecuring large collaborations with strong partners, amidstconsolidation and reorganization in the pharma industry."About Galapagos and BioFocus DPIGalapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery anddevelopment company with small molecule programs in bone and jointdiseases, bone metastasis, cachexia, anti-infectives and metabolicdiseases. Its division BioFocus DPI offers a full suite oftarget-to-drug discovery products and services to pharmaceutical andbiotech companies as well as not-for-profit organizations,encompassing target discovery and validation, screening and drugdiscovery through to delivery of pre-clinical candidates. BioFocusDPI also provides adenoviral reagents for rapid identification andvalidation of novel drug targets, compound libraries for drugscreening as well as ADMET products to select compounds. Galapagoscurrently employs 495 people and operates facilities in sixcountries, with global headquarters in Mechelen, Belgium. More infoat www.glpg.com and www.biofocusdpi.com.CONTACTSGalapagos NVOnno van de Stolpe, CEOTel: +31 6 2909 8028ir(at)glpg.comThis release may contain forward-looking statements, including,without limitation, statements containing the words "believes,""anticipates," "expects," "intends," "plans," "seeks," "estimates,""may," "will," "could," "stands to," and "continues," as well assimilar expressions. Such forward-looking statements may involveknown and unknown risks, uncertainties and other factors which mightcause the actual results, financial condition, performance orachievements of Galapagos, or industry results, to be materiallydifferent from any historic or future results, financial conditions,performance or achievements expressed or implied by suchforward-looking statements. Given these uncertainties, the reader isadvised not to place any undue reliance on such forward-lookingstatements. These forward-looking statements speak only as of thedate of publication of this document. Galapagos expressly disclaimsany obligation to update any such forward-looking statements in thisdocument to reflect any change in its expectations with regardthereto or any change in events, conditions or circumstances on whichany such statement is based, unless required by law or regulation.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 24.09.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 6158
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 312 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos announces expanded drug discovery collaboration with
Schering-Plough"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
